Immunoglobulins
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
Managing comorbidities, ensuring proper dosing, and treating IVIG-related adverse events are areas where pharmacists play a large role.
For patients with multiple myeloma who may experience an infection while receiving teclistamab, supplementation with intravenous immunoglobulin (IVIG) can help resolve and prevent serious complications.
Treatment with IVIG leads to high responses 6 months following the initiation of therapy.
Factors associated with intravenous immunoglobulin (IVIG)-related adverse events include older age, dehydration, and administration of multiple IVIG infusions.
Pharmacists are encouraged to work closely with health care providers to ensure appropriate use of high-cost Intravenous immunoglobulin (IVIG) therapy for BK nephropathy.
Pharmacists can optimize IVIG treatment for BK nephropathy in kidney transplant recipients by educating providers and monitoring for infusion reactions.
Higher costs of efgartigimod alfa are primarily driven by its status as a newly approved, brand-name therapy without a generic alternative.
Often used as a treatment for severe exacerbations of myasthenia gravis, intravenous immunoglobulin can lead to high financial toxicity and resource utilization.
The management of MDS is primarily targeted at controlling or slowing the disease and preventing future complications as much as possible.
A vast majority of patients achieved a positive clinical response with the combination, with improvements in their ocular condition.
Knowledge of recent intravenous immunoglobulin (IVIG) administration in patients receiving the common laboratory test can help inform misdiagnosis.
Intravenous immunoglobulin (IVIG) has proven efficacy in autoimmune neuropathies, with mixed but promising outcomes in severe COVID-19 cases and post-acute sequelae of SARS-CoV-2 infection trials.
No acute serious bacterial infections were observed in a trial of patients with the debilitating immune disorder, a strong mark of safety and tolerability.
IVIG was found to cease development of new lesions and heal previously documented erosions without adverse events to the patient or fetus.
Efforts include a mandatory intravenous immunoglobulin ordering form, blood bank gatekeeping, and a stewardship committee to ensure optimized use.
Intravenous immunoglobulin prescriptions deemed non-compliant according to French national guidelines were more common in younger patients.
Utilizing data from the CHAMPION MG trial, investigators found that many patients had responded to ravulizumab and returned to daily activities within 2 weeks.
Therapy-related complications, in addition to financial obstacles, can complicate myasthenia gravis treatment.
Recognizing repeat dosing efforts is important to improving outcomes in patients with Guillain-Barré syndrome who do not respond to IVIG.
Glucocorticoids improved outcomes for patients with Kawasaki disease at high risk of IVIG resistance without glucocorticoid-related adverse effects.
Though both treatments come with positives and negatives, ultimately, individual patient clinical presentation and accessibility will determine the proper treatment for myasthenic crisis.
By utilizing a lower dose, patients can avoid potential adverse events and high financial burden.
Further trials are required to examine the long-term feasibility of intravenous immunoglobulin (IVIG) for multisystem inflammatory syndrome.
In a patient with long-shedding SARS-CoV-2, transfusion-related acute lung injury developed after intravenous immunoglobulin, emphasizing careful treatment considerations.
Tocilizumab reduced relapses in 4 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
2
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5
